100 likes | 332 Views
Predicting Physical Stability in Q1A(R). Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration Pharmaceutical Science Advisory Committee November 28, 2001. Stress Testing of Drug Substance.
E N D
Predicting Physical Stabilityin Q1A(R) Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration Pharmaceutical Science Advisory Committee November 28, 2001
Stress Testing of Drug Substance • Elevated temperature (in 10°C increment above accelerated temperature) • Humidity (75% or greater) • Effect of pH • Oxidation • Light
Batch Selection of Drug Product • A minimum of 3 batches: 2 should be at least pilot scale; 3rd can be smaller • Same formulation and container/closure as proposed for marketing • Using manufacturing process simulating that for production batches • Meeting same specifications as proposed for marketing
Test Specification • Q1AR: Attributes that are susceptible to change during storage and likely to influence quality, safety, and/or performance • Q1AR: Physical, chemical, microbiological, and biological attributes; functionality test • Q3A/B: Identification and qualification of impurities/degradation products • Q6A: Establishing acceptance criteria for polymorphic forms, particle size, dissolution
Study Long-term Accelerated Intermediate Storage Condition 25°C ± 2°C/ 60% RH ± 5% RH 40°C ± 2°C/ 75% RH ± 5% RH 30°C ± 2°C/ 60% RH ± 5% RH Room Temperature Storage Conditions Data at submission 12 mos from an ongoing study 6 mos from a 6-mo study 6 mos from a 12-mo study
Study Refrigerator Long-term Accelerated Freezer Long-term Accelerated* *(optional) Storage Condition 5°C ± 3°C 25°C ± 2°C/60% RH ± 5% RH -20°C ± 5°C 5°C ± 3°C or 25°C ± 2°C Low Temperature Storage Conditions
Significant Change Criteria • 5% change in assay, or failure to meet acceptance criteria for potency using biological or immunological procedures • Degradation products exceeding acceptance criteria • Failure to meet pH acceptance criteria • Failure to meet acceptance criteria for appearance, physical attributes, functionality test • Failure to meet acceptance criteria for dissolution for 12 dosage units
Consequence of Significant Change • If significant change occurs at accelerated condition, conduct intermediate testing, where applicable; extrapolation of shelf life beyond real-time data may not be granted • If significant change occurs at intermediate condition, consider reformulation, more protective container/closure, shorter shelf life, qualification of higher impurity level
Shelf Life Establishment • Extrapolation of shelf life beyond real-time data can be granted if no significant change at accelerated condition and if supported by supporting data and/or statistical analysis • Post-approval, tentative shelf life should be confirmed by 3 production batches on stability • In the U.S., at least one batch should be put on long-term stability annually thereafter
Predictability of Physical Stability • Predictability of long-term behavior based on physical attributes at accelerated condition • Predictability of future production batch behavior based on data from primary stability batches • Complexity of formulation and dosage form • Robustness of manufacturing process, scale-up • Soundness of sampling plan • Reproducibility of analytical procedure • Meaningful acceptance criteria • Experience; number of primary and supporting batches